药品监管现代化
Search documents
2026年全国药品监督管理工作会议在京召开
Zheng Quan Shi Bao Wang· 2026-01-07 10:41
Core Viewpoint - The national drug supervision work conference emphasized key tasks for 2026 to ensure a good start for the "14th Five-Year Plan," focusing on drug safety, industry development, legal standards, and modernization of drug regulation [1] Group 1: Drug Safety - The conference highlighted the need to ensure high-level drug safety by improving the drug safety responsibility system and enhancing clinical trial supervision [1] - There will be increased inspection and sampling efforts on key varieties, especially those selected in centralized procurement [1] - The initiative includes a "clean source" action in drug distribution and strengthened regulation of online sales to maintain drug safety standards [1] Group 2: Industry Development - The conference aims to support the pharmaceutical industry in improving quality and efficiency through comprehensive reform of drug regulation [1] - It emphasizes early intervention and tailored strategies for key products, promoting innovation in drug research and development [1] - The focus also includes supporting the self-reliance of high-level medical devices and fostering the growth of the beautiful economy [1] Group 3: Legal Framework - Continuous improvement of the drug regulation legal framework is a priority, including enhancing the authority and credibility of administrative law enforcement [1] - There will be increased legal education efforts directed at enterprises and grassroots levels to solidify the legal foundation of drug regulation [1] Group 4: Modernization of Drug Regulation - The conference calls for high-quality development of the "14th Five-Year" drug planning and the promotion of integrated national drug regulation [1] - Strengthening the regulatory talent pool and technical support capabilities is essential, along with advancing regulatory information technology and scientific research applications [1] - The initiative aims to enhance China's international influence in drug regulation and participate actively in global drug safety governance [1]